261) hototherapy in vitro and in vivo in mouse tumor models. |
262) or activity in several leukemic and solid tumor models. |
263) ies involving CX-5461 have promising anti-tumor activity in vivo in neuroblastoma, o |
264) Recent data attributed the tumor-promoting activity of high-fat diets |
265) sulting in secondary bile acids that show tumor-promoting activity. |
266) ng M2 macrophage associated proteins, and tumor angiogenesis by enhancing the activa |
267) MicroRNAs (miRNAs) participate in tumor angiogenesis in NSCLC. |
268) ation and migration are critical steps in tumor angiogenesis. |
269) ic T cell immunity and provided effective tumor control and long-term immunological |
270) ed with SRS so as to investigate rates of tumor control and symptomatic improvement. |
271) circulating immune cells is critical for tumor control. |
272) uired resistance and extended survival of tumor-bearing mice treated with SCD inhibi |
273) In this work, tumor-bearing mice were imaged at 7 T to |
274) Moreover, treatment of breast tumor-bearing mice with C108 resulted in a |
275) the most frequent, lethal, and aggressive tumor of the central nervous system in adu |
276) Ovarian cancer (OC) is a common malignant tumor of the female reproductive system. |
277) young adult woman who developed a myxoid tumor of the pineal region having a SMARCB |
278) anscriptomic alterations in close to 9000 tumor samples across canonical oncogenic s |
279) ssion in genetic mouse models and patient tumor samples. |
280) l reconstruction from single and multiple tumor samples. |
281) PGV can also be identified in tumor sequencing assays, which, when perfo |
282) Excluding these 3 MMR carriers, tumor sequencing identified at least two s |
283) encing (WGS) and targeted and genome-wide tumor sequencing were applied to identify |
284) reatment with a BRAF inhibitor results in tumor shrinkage in several patients. |
285) enib before radiation therapy and similar tumor shrinkage occurred within 16 days. |
286) se of vemurafenib resulted in significant tumor shrinkage that allowed for the compl |
287) combination treatment markedly decreased tumor size, but only DFMO increased surviv |
288) ased host immune response acted to reduce tumor size, suggesting that increasing MPO |
289) We assessed the mean tumor size, ulcer diameter, exposed blood |
290) classification, lymph node metastasis and Tumor-Node-Metastasis stage. |
291) pends on histological differentiation and tumor stage. |
292) f PG for GEJ adenocarcinoma regardless of tumor stage. |
293) sion in urothelial carcinomas or in other tumor types including lung adenocarcinoma, |
|